DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Aromasin (Exemestane) - Summary

 
 



AROMASIN SUMMARY

AROMASIN®
exemestane tablets

AROMASIN® Tablets for oral administration contain 25 mg of exemestane, an irreversible, steroidal aromatase inactivator.

AROMASIN Tablets are indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.


See all Aromasin indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Aromasin (Exemestane)

At 2014 San Antonio Breast Cancer Symposium three new Myriad studies highlighted
Source: Breast Cancer News From Medical News Today [2014.12.13]
Myriad Genetics, Inc. (NASDAQ: MYGN) has announced results from a new study that demonstrated the ability of the myRisk™ Hereditary Cancer test to detect 105 percent more mutations in cancer...

Capecitabine No Benefit in Elderly Breast Cancer Patients
Source: Medscape Hematology-Oncology Headlines [2014.12.12]
The largest breast cancer trial to date of elderly patients found that single-agent capecitabine is no better than forgoing cytotoxic treatment altogether.
Medscape Medical News

New Algorithm for Treatment of Premenopausal Breast Cancer
Source: Medscape Hematology-Oncology Headlines [2014.12.12]
Results from the Suppression of Ovarian Function Trial (SOFT) are practice changing for a subgroup of premenopausal women with breast cancer.
Medscape Medical News

Ovarian suppression reduces recurrence for some young breast cancer patients
Source: Breast Cancer News From Medical News Today [2014.12.12]
The addition of ovarian suppression to adjuvant treatment (post-surgery) with tamoxifen reduced breast cancer recurrence in young women with hormone-sensitive early breast cancer who received...

Some ovarian and breast cancer patients may benefit from manipulation of a non-coding microRNA
Source: Breast Cancer News From Medical News Today [2014.12.12]
A genetic misfire called the 3q26.2 amplicon can cause real havoc. In fact, it is among the most frequent chromosomal aberrations seen in many cancers, including ovarian and breast cancers.

more news >>

Published Studies Related to Aromasin (Exemestane)

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. [2013]
this patient population... CONCLUSION: The addition of everolimus to exemestane markedly prolonged PFS in

Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. [2013]
alone... CONCLUSION: Entinostat added to exemestane is generally well tolerated and

Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. [2013]
(HRQOL)... CONCLUSIONS: In patients with advanced breast cancer who develop disease

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. [2013]
hormone-receptor-positive breast cancer... INTERPRETATION: Addition of ganitumab to endocrine treatment in women with

Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. [2012]
of potential widespread use, we examined the safety of exemestane on bone health... INTERPRETATION: 2 years of treatment with exemestane worsens age-related bone

more studies >>

Clinical Trials Related to Aromasin (Exemestane)

Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer [Active, not recruiting]
To compare recurrence free survival between two treatment groups (5 years with exemestane vs 2. 5 to 3 years tamoxifen followed by 2 to 2. 5 years of exemestane for a total duration of 5 years)

Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women [Terminated]
The purpose of this study is to find out if the two different formulations of exemestane (Aromasin), oral and injectable, are equivalent in terms of pharmacodynamics and pharmacokinetics, i. e., if ultimately both formulations have the same efficacy in postmenopausal women with metastatic breast cancer who have failed previous antiestrogens therapy and are equally safe.

An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin [Recruiting]
To generate the following data from patients with early breast cancer treated with Aromasin® in the adjuvant setting in India.

- Efficacy of the treatment with Aromasin®

- Safety of the treatment with Aromasin®

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer [Active, not recruiting]
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin (exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer. Patients will be treated until disease progression or until the investigator has determined that treatment is not in the best interest of the patient, whichever occurs first.

Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients [Recruiting]
The purpose of this study is to assess the safety and effectiveness of AZD4547 in combination with fulvestrant vs. fulvestrant alone in ER+ breast cancer patients with FGFR1 polysomy (FISH4/5) or gene amplification (FISH 6)

more trials >>

Reports of Suspected Aromasin (Exemestane) Side Effects

Arthralgia (31)Alopecia (20)Disease Progression (19)Breast Cancer (18)Fatigue (14)Pain (13)Abdominal Distension (12)Rash (12)Bone Pain (11)Headache (11)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 2 ratings/reviews, Aromasin has an overall score of 8.50. The effectiveness score is 9 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
 

Aromasin review by 57 year old female patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   Breast Cancer
Dosage & duration:   5mg taken 1/day for the period of 3 years
Other conditions:   under-active thyroid
Other drugs taken:   Synthroid
  
Reported Results
Benefits:   Aromasin's treatment benefits are unknown. I have not had a reoccurance of breast cancer while on the drug, though unsure we can attribute that with the drug treatment itself. Perhaps there are other positive health-related items coming into play, such as exerciase and eating habits. Not aware of any side effects or adverse reactions. Drug is very expensive, however.
Side effects:   As mentioned above, I have not had any side effects from Aromasin other than hot flashes and night sweats. These may be due to menopause rather than the treatment itself. The hot flashes have been relatively mild and can be controlled, for the most part, by limiting or removing all alcoholic beverages.
Comments:   After breast cancer treatment of chemo. and radiation I was put on Tamoxifen for several years, about 5 years. After Tamoxifen, it was recommended that I start taking Aromasin, which I have done for about 3 years. My doctor said it is not known how long women should be on Aromasin and still receeve a benefit from taking the drug.

 

Aromasin review by 58 year old female patient

  Rating
Overall rating:  
Effectiveness:   Highly Effective
Side effects:   Moderate Side Effects
  
Treatment Info
Condition / reason:   eostrogen-positive breast cancer
Dosage & duration:   25mg taken daily for the period of 4 years
Other conditions:   high blood pressure
Other drugs taken:   various blood pressure medications
  
Reported Results
Benefits:   During the 4 years so far [out of 5], I have had no recurrance of the tumour and no additional tumours have been detected by ultra-sound, mammogram, and twice-yearly check-ups. Perhaps the greatest benefit is the gradual reduction in stress experienced as a result of my on-going stabilised condition after a lumpectomy.
Side effects:   I had some initial swelling of my hip, knee and ankle joints in the morning which slowly subsided during the day. The medication also aggravated the hot-flushes of the menopause, making them initially frequent and copious, and on-going for the treatment duration so far - tho with reduced frequency now in Year 4. I also experience considerable thirst.
Comments:   I was put on Aromasin after 6 months on Tamoxifen because I suffered debilitating muscle cramps on Tamoxifen as well as joint problems and extreme hot flushes. Aromasin has been kinder, and so far I have taken it daily for 4 years out of an initial 5. It may be prescribed beyond 5 years, I'm not sure. It has relatively slight side effects now but in the first 6 months I was conscious of its effects on my body - not intolerable by any means, just noticable.

See all Aromasin reviews / ratings >>

Page last updated: 2014-12-13

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014